High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

Stanford University35 enrolled

Overview

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma, Non-Hodgkin Blood and Marrow Transplant (BMT)Lymphomas: Non-Hodgkin

Interventions

ablative allogeneic hematopoietic cell transplantationPROCEDURE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 61 Years

Medical Language ↔ Plain English

Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma Age: \>18 and \<61 years of age Signed informed consent Exclusion Criteria:Hepatic dysfunction defined by serum transaminases \>2.5X normal values Serum creatinine of \> 2 mg/dl or creatinine clearance \< 60 ml/min Diseases other than non-Hodgkin's lymphoma Prior bone marrow transplant procedure Severe psychological or medical illness

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Outcomes

Primary Outcomes

Safety

Toxicity

Efficacy

Secondary Outcomes

Incidence of acute and chronic GVHD

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.